Acrivon Therapeutics (ACRV) said Friday that the first patient has been dosed in its phase 1 clinical trial evaluating ACR-2316, which is being developed to treat patients with solid tumors.
The company said the trial will determine the maximal tolerated dose and recommended phase 2 monotherapy dose, characterization of the pharmacokinetic profile and preliminary evaluation of anti-tumor activity.
Price: 7.00, Change: +0.02, Percent Change: +0.29
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。